Park ZW - Search Results

1

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.

Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW, Oh WY, Kim JM, Choi SE. Ryu S, et al. Among authors: park zw. Clin Transl Sci. 2017 Mar;10(2):93-101. doi: 10.1111/cts.12451. Epub 2017 Mar 14. Clin Transl Sci. 2017. PMID: 28296334 Free PMC article. Clinical Trial.

2

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.

Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM, Oh WY, Na HS, Lee JG, Seo DW, Hwang IY, Park Z, Jang IJ, Oh J, Choi SE. Park S, et al. J Korean Med Sci. 2017 May;32(5):729-736. doi: 10.3346/jkms.2017.32.5.729. J Korean Med Sci. 2017. PMID: 28378544 Free PMC article.

3

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers.

Jung E, Ryu S, Park Z, Lee JG, Yi JY, Seo DW, Lee J, Jeong HS, Kim JM, Oh WY. Jung E, et al. J Korean Med Sci. 2018 May 23;33(27):e182. doi: 10.3346/jkms.2018.33.e182. eCollection 2018 Jul 2. J Korean Med Sci. 2018. PMID: 29962926 Free PMC article.

4

The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.

Jiang F, Choi JY, Lee JH, Ryu S, Park ZW, Lee JG, Na HS, Lee SY, Oh WY, Chung MW, Choi SE. Jiang F, et al. Among authors: park zw. Pharmacogenomics. 2017 Apr;18(5):459-469. doi: 10.2217/pgs-2016-0199. Epub 2017 Mar 28. Pharmacogenomics. 2017. PMID: 28350522 Clinical Trial.

5

ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.

Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH. Jung ES, et al. J Gastroenterol Hepatol. 2019 Oct;34(10):1727-1735. doi: 10.1111/jgh.14652. Epub 2019 Apr 1. J Gastroenterol Hepatol. 2019. PMID: 30851117

6

Well-defined differentiation of hESC-derived hemangioblasts by embryoid body formation without enzymatic treatment.

Gil CH, Lee JH, Seo J, Park SJ, Park Z, Kim J, Jung AR, Lee WY, Kim JS, Moon SH, Lee HT, Chung HM. Gil CH, et al. Biotechnol Lett. 2015 Jun;37(6):1315-22. doi: 10.1007/s10529-015-1786-4. Epub 2015 Feb 21. Biotechnol Lett. 2015. PMID: 25700820

7

High content screening for compounds that induce early stages of human embryonic stem cell differentiation.

Jee J, Jeon H, Hwang D, Sommer P, Park Z, Cechetto J, Dorval T. Jee J, et al. Comb Chem High Throughput Screen. 2012 Sep;15(8):656-65. doi: 10.2174/138620712802650540. Comb Chem High Throughput Screen. 2012. PMID: 22364550

8

Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.

Kim MG, Kim D, Suh SK, Park Z, Choi MJ, Oh YK. Kim MG, et al. Arch Pharm Res. 2016 Apr;39(4):437-452. doi: 10.1007/s12272-016-0719-7. Epub 2016 Feb 19. Arch Pharm Res. 2016. PMID: 26895243 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters